

ASX ANNOUNCEMENT

5<sup>TH</sup> MARCH 2020

RESPIRI

A Breath of Fresh Ideas



## FIRST BATCH OF WHEEZOS DELIVERED

**Respiri Limited (ASX:RSH)** is pleased to announce a milestone in the progression of Respiri towards commercialisation in the fourth quarter of calendar 2020.

The first batch of the initial order of 500 wheezos has been delivered by SRX to Respiri's product team. The Company can confirm that 95% of the units passed compliance testing and Respiri's team are very pleased with the performance of these units.

The units will be deployed in a patient and clinician experiential program Respiri is currently planning to implement in the second quarter of calendar 2020. This program will provide clinicians & patients full access to the wheezo® eHealth SaaS platform and, in the process, help RSH gain important data and insights that will be key for the full commercial launch scheduled for the fourth quarter of calendar 2020.

The delivery, and acceptance, of these units represents the achievement of a significant milestone in the manufacturing process. Production volumes will ramp up over coming weeks with the full quantity of 500 wheezos expected to be available to Respiri by early April.

Alastair Beard  
Company Secretary  
alastair@respiri.co

This ASX announcement dated 5 March 2020  
has been authorised for release by the Board of Directors of Respiri Limited.

--END--

## **ABOUT RESPIRI LIMITED**

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

## **FORWARD LOOKING STATEMENTS**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.